Abstract:Chimeric antigen receptor (CAR) T-cell therapy has become the standard of care for children and young adults with relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL), and it is a highly promising therapy under investigation for adults with relapsed disease. Despite having potentially life-threatening toxicities, such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, the benefits of CAR T-cell therapy far outweigh these risks, particularly as increased experience and improved supportive care measures are mitigating these toxicities. CAR T cells can result in complete remission for significant proportion of patients with relapsed and refractory B-ALL and permit them to proceed to potentially curative allogeneic hematopoietic stem cell transplantation (allo-HSCT). CAR T cells may also be curative by themselves. Herein lie the greatest challenges and questions for clinical investigators, specifically, how are CAR T cells best employed and how do we overcome mechanisms of resistance to them? The primary clinical question is the timing and even the necessity of allo-HSCT. Relative to resistance, we know that target antigen loss, specifically CD19, is a major contributor to resistance. However, current investigations of alternative targets, such CD22, and CAR T cells expressing dual targeting antigen receptors have demonstrated encouraging initial results and provide a high degree of optimism that the efficacy and the broader application of CAR T-cell therapy will gradually increase in B-ALL. That optimism is not as high and the challenges are increased for the application of CAR T cells in T-cell leukemias and acute myeloid leukemia due to the relative lack of suitable leukemia surface targets that are not also expressed on normal hematopoietic progenitors. Despite these significant challenges, considerable research is being conducted into the development of CAR T cells for these diseases utilizing unique technologies, which may be applicable to other diseases.

CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH Annual Meeting

Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances

Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meeting

Current state of CAR-T therapy for T-cell malignancies

CAR T-cell therapy in acute myeloid leukemia

Novel Cellular Immunotherapies for Hematological Malignancies: Recent Updates from the 2021 ASH Annual Meeting

CAR T Cells in T Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Recent advances in CAR-T therapy for the treatment of acute myeloid leukemia

Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia

CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities

Chimeric Antigen Receptor T Cell Therapy for Acute Leukemia

Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia

Overcoming the challenges encountered in CAR-T therapy: latest updates from the 2023 ASH annual conference

Targeted treatment of T-cell acute lymphoblastic leukemia: latest updates from the 2022 ASH Annual Meeting

Current Status of CAR T Cell Therapy for Leukemias

Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies

Recent progress in chimeric antigen receptor therapy for acute myeloid leukemia

Current Progress in CAR-T Cell Therapy for Hematological Malignancies

Advances in CAR-T-cell therapy in T-cell malignancies